<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05099289</url>
  </required_header>
  <id_info>
    <org_study_id>DOC-10154</org_study_id>
    <nct_id>NCT05099289</nct_id>
  </id_info>
  <brief_title>Parasternal Access for Substernal Shocks and Pacing With an acUtely Placed Less-invasive Lead for EV-ICD (PASS PULL EV-ICD) Study</brief_title>
  <acronym>PASS PULL</acronym>
  <official_title>Parasternal Access for Substernal Shocks and Pacing With an acUtely Placed Less-invasive Lead for EV-ICD (PASS PULL EV-ICD) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AtaCor Medical, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AtaCor Medical, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The PASS PULL Study is a prospective, multi-center, single-arm study without concurrent or&#xD;
      historical controls. This initial concept feasibility study is primarily intended to&#xD;
      demonstrate that the EV-ICD Lead can be safely positioned within the anterior mediastinum as&#xD;
      intended using the AtaCor delivery system. The study will secondarily characterize the&#xD;
      ability for the EV-ICD Lead to facilitate VF sensing and defibrillation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the study is to demonstrate that the AtaCor EV-ICD Lead can be&#xD;
      safely positioned within the anterior mediastinum as intended using the EV-ICD Dilator and&#xD;
      EV-ICD Delivery Tool. The study will secondarily characterize the ability for the EV-ICD Lead&#xD;
      to facilitate VF sensing and defibrillation.&#xD;
&#xD;
      Up to 3 Investigational Sites will participate with up to 20 subjects enrolled in the study.&#xD;
      Patients undergoing de novo or replacement ICD procedure will be eligible for participation.&#xD;
      Study participation requires acute evaluation of the EV-ICD Lead during the index procedure.&#xD;
      Echocardiography will be used to evaluate any new or worsening pericardial effusions. A&#xD;
      follow-up visit will occur 7-10 days post-removal via phone, video call, or in-person.&#xD;
      Participation will end after completion of the 7-10 days post-removal visit. The Study is&#xD;
      expected to last up to 3 months for enrollment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of SADEs</measure>
    <time_frame>Up to 10 days post-procedure</time_frame>
    <description>Incidence of Serious Adverse Device Effects (SADEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of Insertion Success</measure>
    <time_frame>Procedure</time_frame>
    <description>Defined as the ability to deploy the lead in a position within the mediastinum that is suitable for defibrillation testing and does not result in one (1) or more SADEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functionality - Lowest Defibrillation Conversion Energy</measure>
    <time_frame>Procedure</time_frame>
    <description>Lowest Defibrillation Conversion Energy (J)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observational: Incidence of ADEs</measure>
    <time_frame>Up to 10 days post-procedure</time_frame>
    <description>Incidence of Adverse Device Effects (ADEs), Overall and Individual</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ventricular Arrythmia</condition>
  <condition>Ventricular Tachycardia</condition>
  <condition>Ventricular Fibrillation</condition>
  <arm_group>
    <arm_group_label>AtaCor EV-ICD Lead System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects inserted with the AtaCor EV-ICD Lead Model AC-7000</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AtaCor EV-ICD Lead</intervention_name>
    <description>Subjects will receive the AtaCor EV-ICD Lead being evaluated in the study.</description>
    <arm_group_label>AtaCor EV-ICD Lead System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          1. At least 18 years old&#xD;
&#xD;
          2. Indicated for de novo or replacement ICD procedure&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. NYHA IV functional class&#xD;
&#xD;
          2. BMI ≥ 35 kg/m2&#xD;
&#xD;
          3. Inotropic therapy in past 180 days&#xD;
&#xD;
          4. Subjects with a hemodynamically unstable intrinsic heart rate that requires continual&#xD;
             ventricular pacing&#xD;
&#xD;
          5. Presence or planned use of subcutaneous coils/arrays, epicardial patches or epicardial&#xD;
             pace/sense leads&#xD;
&#xD;
          6. Subjects on anticoagulation/antiplatelet therapy that cannot be temporarily&#xD;
             discontinued for the procedure&#xD;
&#xD;
          7. Logistical or safety related circumstances that may prevent data collection or&#xD;
             follow-up&#xD;
&#xD;
          8. Participation in any concurrent clinical study without prior written approval from the&#xD;
             Sponsor&#xD;
&#xD;
          9. Inability to give an informed consent to participate in the Study&#xD;
&#xD;
             Known prior history for any of the following:&#xD;
&#xD;
         10. Structural abnormalities of the heart that may increase risk of the study procedure or&#xD;
             an obstructed/restricted pathway into the mediastinum for the EV-ICD Dilator, EV-ICD&#xD;
             Delivery Tool and EV-ICD Lead as assessed from available CT or Echocardiography.&#xD;
&#xD;
         11. Uncontrolled paroxsymal, persistent or permanent atrial fibrillation&#xD;
&#xD;
         12. Median or partial sternotomy&#xD;
&#xD;
         13. Surgery with disruption of the lung, pericardium or connective tissue between the&#xD;
             sternum and pericardium&#xD;
&#xD;
         14. Significant anatomic derangement of or within the thorax (e.g., pectus excavatum,&#xD;
             significant scoliosis)&#xD;
&#xD;
         15. Thoracic radiation therapy, pneumothorax, pneumomediastinum or other medical&#xD;
             treatments/conditions which may complicate the EV-ICD Lead insertion procedure&#xD;
&#xD;
         16. Pericardial disease, pericarditis and mediastinitis&#xD;
&#xD;
         17. Medical treatments, surgeries or conditions that increase the potential for&#xD;
             pericardial adhesions&#xD;
&#xD;
         18. FEV1 &lt; 1.0 Liter&#xD;
&#xD;
         19. Surgically corrected congenital heart disease (not including catheter-based&#xD;
             procedures)&#xD;
&#xD;
         20. Allergies to the device materials as listed in the Instructions for Use (IFU)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin C Burke, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>AtaCor Medical, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Husby, MS, MPH</last_name>
    <phone>+1 949-392-8988</phone>
    <email>michael@atacor.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sarah Hase, BS, CCRA</last_name>
    <phone>+1 949-545-9820</phone>
    <email>sarah@atacor.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sanatorio Italiano</name>
      <address>
        <city>Asunción</city>
        <country>Paraguay</country>
      </address>
    </facility>
    <contact>
      <last_name>Santiago Gallo, MD</last_name>
      <phone>21 202767</phone>
      <email>santigallo56@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Adrian Ebner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Paraguay</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>September 29, 2021</study_first_submitted>
  <study_first_submitted_qc>October 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2021</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ventricular Defibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
    <mesh_term>Ventricular Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

